![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1618226
°üÀýÅë ÁÖ»ç ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2024-2032³â)Joint Pain Injections Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032 |
°üÀýÅëÁõ ÁÖ»çÁ¦ ¼¼°è ½ÃÀåÀº 2023³â 36¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024-2032³â°£ ¿¬Æò±Õ 7.7% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ³ëÀÎ Àα¸ Áõ°¡¿Í Á¤Çü¿Ü°ú ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÁÖ»çÁ¦ À¯Çü¿¡ µû¶ó È÷¾Ë·ç·Ð»ê ÁÖ»ç, ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å ÁÖ»ç, ´ÙÇ÷¼ÒÆÇ Ç÷Àå ÁÖ»ç·Î ³ª´µ¸ç, 2023³â¿¡´Â È÷¾Ë·ç·Ð»ê Áֻ簡 64.8%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 7.9%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àα¸ °í·ÉÈ¿Í Çõ½ÅÀûÀÎ Á¦Ç°ÀÇ Ã¤ÅÃÀÌ °áÇÕÇÏ¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½Å¼ÓÇÑ ÀÓ»ó °á°ú¸¦ Á¦°øÇÏ´Â ÃÖ¼Òħ½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼ È÷¾Ë·ç·Ð»ê Áֻ翡 ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. È÷¾Ë·ç·Ð»ê ÁÖ»ç´Â ÁÖ·Î ¹«¸ °ñ°üÀý¿° Ä¡·á¿¡ »ç¿ëµÇ¸ç, °üÀý ³» ġȯ¼ú·Î ¾Ë·ÁÁø ¹æ¹ýÀ¸·Î °üÀý ±â´ÉÀ» °³¼±ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. °üÀýÅë ÁÖ»ç ½ÃÀåÀº ¹«¸, ¾î±ú ¹× ÆÈ²ÞÄ¡, ¹ß¸ñ, °í°üÀý, ±âŸ °üÀý µî °üÀý À¯Çüº°·Îµµ ºÐ·ùµË´Ï´Ù. ¹«¸ °üÀý ºÎ¹®Àº ºÐ¼® ±â°£ µ¿¾È 27¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â Å« ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ °°Àº ±Þ°ÝÇÑ ¼ºÀåÀº ¹«¸ °ü·Ã Áúȯ, ƯÈ÷ ¿¬°ñ°ú »À°¡ Á¡Â÷ÀûÀ¸·Î ¾ÇȵǴ °ñ°üÀý¿°ÀÇ ³ôÀº À¯º´·üÀÌ ÁÖ¿ä ¿øÀÎÀÔ´Ï´Ù. ³ë³âÃþ¿¡¼ ÈçÇÑ ÁúȯÀÎ ¹«¸ °ñ°üÀý¿°Àº ºÒÆíÇÔ°ú ¿îµ¿ Á¦ÇÑÀ» ÃÊ·¡ÇÕ´Ï´Ù. Ç¥ÁØ Ä¡·á¹ý¿¡´Â ¹°¸®Ä¡·á, ÀçȰġ·á, ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦, È÷¾Ë·ç·Ð»ê °üÀý ³» ġȯ¼ú µîÀÌ Æ÷ÇԵǸç, °üÀýÅë ÁÖ»ç´Â ÀÌ·¯ÇÑ Áõ»óÀ» °ü¸®ÇÏ´Â µ¥ ÀÖ¾î °üÀýÅë ÁÖ»çÀÇ Á߿伺À» °Á¶Çϰí ÀÖ½À´Ï´Ù. Áö¿ªº° ºÐ¼®¿¡¼´Â ºÏ¹Ì°¡ 2023³â 47.4%·Î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÇâÈÄ ¸î ³âµ¿¾È Å« ÆøÀÇ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ ¿¬µµ | 2023³â |
¿¹Ãø ¿¬µµ | 2024-2032³â |
½ÃÀÛ °¡°Ý | 36¾ï ´Þ·¯ |
¿¹»ó °¡°Ý | 72¾ï ´Þ·¯ |
CAGR | 7.7% |
ÀÌ °°Àº ¿ìÀ§´Â ÁÖ·Î °üÀý¿° ¹× ±âŸ Á¤Çü¿Ü°ú ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÷´Ü Ä¡·á ¿É¼ÇÀÇ ºü¸¥ µµÀÔ¿¡ ±âÀÎÇÕ´Ï´Ù. ½ºÆ÷Ã÷ ¹× »ç°í·Î ÀÎÇÑ ºÎ»ó Áõ°¡, °í·ÉÈ Àα¸ÀÇ °üÀý Áúȯ À¯º´·ü Áõ°¡, Ä¡·á ¼Ö·ç¼ÇÀÇ Áö¼ÓÀûÀÎ Çõ½ÅÀº ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
The Global Joint Pain Injections Market was valued at USD 3.6 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2032. The increasing elderly population and the rising incidence of orthopedic conditions drive this market's expansion. The market is divided by injection type into hyaluronic acid injections, corticosteroid injections, and platelet-rich plasma injections. In 2023, hyaluronic acid injections dominated the market with a 64.8% revenue share and are expected to experience a notable CAGR of 7.9% during the forecast period. The combination of an aging demographic and the introduction of innovative products is anticipated to boost market growth.
There is a growing preference for minimally invasive procedures that deliver rapid clinical outcomes, further enhancing the demand for hyaluronic acid injections. These injections are primarily used for treating knee osteoarthritis and are recognized for their ability to improve joint function through a method known as viscosupplementation. The joint pain injections market is also categorized by joint type, including knee, shoulder and elbow, ankle, and hip, as well as other joints. The knee segment is expected to experience significant growth, with projections indicating it will reach USD 2.7 billion during the analysis period.
This surge is largely driven by the high prevalence of knee-related disorders, particularly osteoarthritis, characterized by the gradual deterioration of cartilage and bone. As a common ailment among the elderly, osteoarthritis leads to discomfort and restricted mobility. Standard treatment options often include physical therapy, rehabilitation, non-steroidal anti-inflammatory drugs, and viscosupplementation with hyaluronic acid, underscoring the importance of joint pain injections in managing these conditions. In terms of regional analysis, North America held the largest market share at 47.4% in 2023, with substantial growth anticipated in the upcoming years.
Market Scope | |
---|---|
Start Year | 2023 |
Forecast Year | 2024-2032 |
Start Value | $3.6 Billion |
Forecast Value | $7.2 Billion |
CAGR | 7.7% |
This dominance is primarily attributed to the rising incidence of arthritis and other orthopedic disorders, alongside the swift adoption of advanced treatment options. The growing prevalence of joint conditions among the aging population, in line with an increase in injuries from sports and accidents, as well as continuous innovation in therapeutic solutions, are vital factors driving market growth in this region.